Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Randomized clinical trial to compare the efficacy of different doses of oral isotretinoin 10
mg/day, 20 mg/day and 30 mg/day during 12 weeks for the treatment of facial recalcitrant flat
warts. The primary endpoint will be the proportion of participants with total remission of
facial flat warts at the end of the intervention in the three arms of the clinical trial.